NetworkNewsBreaks – Predictive Oncology Inc. (NA
Post# of 280
Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into a $15 million common stock purchase and registration rights agreement with Oasis Capital, LLC, a Puerto Rico limited liability company. Under the agreement, upon satisfaction of its conditions including the effectiveness of a resale registration statement, which has occurred, Predictive Oncology has the right to sell up to $15 million of its common stock to Oasis Capital over a 36-month period. “With this equity line established, the financial road ahead for Predictive Oncology has truly begun to smooth out,“ POAI CEO Dr. Carl Schwartz said in the news release. “This equity line should eliminate the need to go to the capital markets for operational financing for the foreseeable future.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer